Epidemiological Insights into Invasive Fungal Rhinosinusitis among COVID-19 Inpatients: Unveiling Diverse Pathogens with implications on cancer patients

Patro, Mane, Rami, Ojha, Kaushik and Swathi

Health Leadership and Quality of Life, 2025, vol. 4, 591

Abstract: The emergence of invasive fungal rhinosinusitis (IFRS), as well as COVID-19 at the same time, poses a challenge to patients receiving treatment in hospitals. Research have shown various infections caused by fungi that relate to the epidemiology of invasive fungal rhinosinusitis among patients suffering from COVID-19. In this retrospective analysis, examined mycological investigations, subject characteristics, clinical manifestations, antifungal drugs used and length of illness among 68 patients diagnosed with Acute Invasive Fungal Rhino-Sinusitis (AIFRS). The research results indicated that steroid therapy was applied in 32.81% of cases and more than half of examines were men. The necessity for early detection is highlighted by the variety of clinical symptoms of headaches (22.40%). Tissue culture, histological analysis and molecular identification of culture isolates were all part of the mycological research. Amphotericin B (30.21%) and Nystatin (22.40%) were the antifungal drugs utilized, indicating a customized approach to therapy. The length of the disease varied by 22.92% of patients reported symptoms lasting between 16 and 30 days. The age distribution showed that the 50 to 59 age group accounted for a significant amount (13.02%). The research highlights the vital need for caution while identifying and treating AIFRS in COVID-19 inpatients, with a focus on a variety of infections and specialized treatment modalities.

Date: 2025
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:health:v:4:y:2025:i::p:591:id:591

DOI: 10.56294/hl2025591

Access Statistics for this article

More articles in Health Leadership and Quality of Life from AG Editor
Bibliographic data for series maintained by Javier Gonzalez-Argote ().